• Bookmark and Share

Preeclampsia Foundation and Biomarkers in the News

Last Updated on Tuesday, December 03, 2013

Yesterday, Chemical & Engineering News featured an article about the early detection of preeclampsia. Preeclampsia Foundation Executive Director Eleni Tsigas was interviewed, and the leading tests to identify and predict the life-threatening pregnancy complication were reviewed. The Preeclampsia Foundation eagerly observes and applauds the advances being made in molecular tests (biomarkers) to confirm diagnosis of preeclampsia and to predict early in pregnancy a woman’s likelihood of developing preeclampsia.

“Biomarkers are leading tests to identify the life-threatening pregnancy complication before it becomes deadly,” reports Celia Henry Arnaud, author of “Early Detection of Preeclampsia” in the December 2, 2013 issue of Chemical & Engineering News.

Noted among the innovators working in this area were:

Alere, a multinational corporation of several diagnostic and health management companies, working on a diagnosis confirmation test based on placental growth factor (PlGF). (See GUEST BLOG in this newsletter, below.)

Screening for Pregnancy Endpoints (SCOPE) Consortium, which has established a biobank of samples from approximately 6,000 pregnant women in the U.K., Australia, New Zealand, and Ireland. The consortium has focused on healthy, low-risk women in their first pregnancy. Samples from this study are being used to help develop predictive tests.   

Thermo Fisher Scientific and PerkinElmer, both of which use biomarkers to calculate a risk score that the mother will develop preeclampsia before 34 weeks. These screening tests are meant to be used at the end of the first trimester, approximately between weeks 10 and 14.

Pronota, a company in Ghent, Belgium, which is working on a predictive test, using four biomarkers, that will be administered halfway through a pregnancy, at week 20.  

Carmenta Bioscience, based in Palo Alto, California, which is also working on a predictive test and a diagnosis confirmation test.

Metabolomic Diagnostics, a company based in Cork, Ireland, which has used samples from the SCOPE study to identify metabolites for development of a predictive test that can be used early in pregnancy.


We’ll be Speaking Here

International Society for the study of Hypertension in Pregnancy
October 23, 2016
San Paulo, Brazil


Mississippi Perinatal Quality Collaborative
October 24, 2016
Illinois Perinatal Quality Collaborative Annual Meeting
November 3, 2016
Lombard, IL
Florida Perinatal Quality Collaborative
Preeclampsia Experts - Florida Road Tour
November 8-10, 2016
Multiple Florida Locations
Association of Women's Health, Obstetric and Neonatal Nurses
November 17, 2016
Monroe Township, New Jersey
Grand Rounds, University of Miami
December 15, 2016
Miami, Florida

Invite Us to Speak at Your Event


Preeclampsia in the News

Featured Video

What’s Happening on Twitter

Preeclampsia RT @cmqcc: CMQCC is grateful and honored to receive the @LamazeAdvocates Presidents Award for our work to improve maternal health #Lamaze1
Preeclampsia RT @cmqcc: Partners in making birth safe & healthy, improving outcomes for mothers & babies #lamaze16 https://t.co/zZYwdI0GbY
Preeclampsia We're excited to head down to #Lamaze16 today! Come see the delightful @LaneyPoye at booth #8! <3

Press Releases by Year

Other Resources

JOIN OUR MAILING LIST. We respect your privacy.